Hikma Pharmaceuticals Shares Plunge 16% on Weak 2026 Financial Guidance

Key Facts

1Hikma Pharmaceuticals shares fell 16% to 1,390p.

22025 results were in line with forecasts, but 2026 guidance was weaker than expected.

3Executive chair Said Darwazah will become full-time CEO for the next two years.

Hikma Pharmaceuticals PLC saw its shares tumble by 16% to 1,390p following the release of its latest financial outlook. While the company's 2025 results met analyst expectations, its guidance for 2026 fell significantly short of market forecasts. This disappointing outlook overshadowed the announcement of a share buyback program, triggering a sharp sell-off among investors. Alongside the financial update, the company announced that Executive Chair Said Darwazah will assume the role of full-time CEO for the next two years. Additionally, CFO Khalid Nabilsi has been appointed as Deputy CEO to support the leadership transition. Analysts suggest that the double-digit decline reflects deep investor concern over future growth prospects and the conservative earnings targets provided.